Logo

Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15

  1. Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  2. Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  3. Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  4. Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  5. Ophthalmology and Rheumatology, Hospital Clinic, Barcelona, Spain.
  6. Ophthalmology and Rheumatology, Hospital Clinic, Barcelona, Spain.
  7. Ophthalmology and Rheumatology, Hospital Clinic, Barcelona, Spain.
  8. Ophthalmology, Hospital de León, Spain.
  9. Rheumatology, Hospital de Donostia, San Sebastian, Spain.
  10. Ophthalmology, Hospital Clínico Universitario San Carlos, Madrid, Spain.
  11. Ophthalmology, Hospital de Pontevedra, Spain.
  12. Ophthalmology, Hospital Miguel Servet Zaragoza, Spain.
  13. Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  14. Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. miguelaggay@hotmail.com
  15. Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. rblanco@humv.es

CER10591 Submission on line
2018 Vol.36, N°4 - PI 0652, PF 0657
Reviews

Free to view (click on article PDF icon to read the article)

Rheumatology Article

 

Abstract

OBJECTIVES:
To assess the efficacy of golimumab (GLM), a fully humanised anti-TNF-α monoclonal antibody, in refractory juvenile idiopathic arthritis (JIA)-associated uveitis.
METHODS:
This was a multicentre study of JIA-associated uveitis refractory to standard synthetic immunosuppressive drugs and in most cases to other anti-TNF-α agents. Results were expressed as mean±standard deviation or as median (range or interquartile range). The Wilcoxon signed-rank test was used to compare continuous variables. A literature review of the efficacy of GLM in uveitis related to JIA was also conducted.
RESULTS:
We studied 7 patients (5 females; mean age 21.7±7.5 years; 13 affected eyes). Uveitis was bilateral in 6. Cystoid macular oedema (CME) occurred in 3 patients (5 eyes). Besides corticosteroids and synthetic immunosuppressive drugs, patients had received before GLM a median of 2 biologic agents (range 0-3) including adalimumab (n=6), etanercept (n=2), infliximab (n=3) and abatacept (n=2). GLM dose was 50 mg/sc every 4 weeks. After 6 months of therapy the number of anterior chamber cells decreased from 1 [0.25–1.5] to 0 [0–0.5] (p=0.02) and optical coherence tomography (in patients with CME) from 313.6±77.05 to 261.4±75.1 μm (p=0.03). The best-corrected visual acuity increased from 0.5 to 0.62 (p=0.018). Complete remission of uveitis was achieved in 4 of 7 patients after 16.8±11.4 months of follow-up. However, 2 of the seven patients had to be switched to tocilizumab due to inefficacy. Local erythema at the injection site was observed in 2.
CONCLUSIONS:
GLM may be considered in the management of refractory JIA-related uveitis.

PMID: 29303704 [PubMed]

Received: 19/05/2017 - Accepted : 05/10/2017 - In Press: 15/12/2017 - Published: 19/07/2018